Schlusskurs
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
2,939 EUR | -.--% | -.--% | -.--% |
24.06. | Sektor-Update: Aktien des Gesundheitswesens legen am Montagnachmittag zu | MT |
24.06. | Sektor Update: Gesundheitswesen | MT |
Kurzporträt
Mitarbeiterzahl: 62
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Monoclonal Antibodies
100,0
%
| 0 | nan % | 0 | 100,0 % | - |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | nan % | 0 | 100,0 % | - |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Renfeng Guo
FOU | Founder | 53 | 01.12.07 |
Niels Riedemann
FOU | Founder | 51 | 01.12.07 |
Thomas Taapken
DFI | Director of Finance/CFO | 59 | 01.10.20 |
Camilla Chong
CTO | Chief Tech/Sci/R&D Officer | 58 | 01.07.23 |
Daniel Vetter
CTO | Chief Tech/Sci/R&D Officer | - | 01.07.22 |
Maria Habel
CTO | Chief Tech/Sci/R&D Officer | 41 | 01.01.08 |
Bruce P. Burnett
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.20 |
Jan Medina
IRC | Investor Relations Contact | - | 22.02. |
Nicole Bertsch
HRO | Human Resources Officer | - | 01.03.21 |
Christian Schmid
LAW | General Counsel | - | 01.01.21 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Nicolas Fulpius
FOU | Founder | 51 | 01.12.07 |
Niels Riedemann
FOU | Founder | 51 | 01.12.07 |
Renfeng Guo
FOU | Founder | 53 | 01.12.07 |
Hege Hellstrom
BRD | Director/Board Member | 59 | 01.04.23 |
Richard Brudnick
BRD | Director/Board Member | 67 | 14.02.19 |
Anthony Gibney
BRD | Director/Board Member | 53 | 06.02.18 |
Mark Kubler
BRD | Director/Board Member | 49 | 01.01.15 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 58 883 272 | 54 560 784 ( 92,66 %) | 0 | 92,66 % |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
InflaRx GmbH
InflaRx GmbH BiotechnologyHealth Technology InflaRx GmbH operates as a biotech company which develops new therapeutics in the field of inflammation. It focuses on the general area of inflammation including indications such as SIRS and SEPSIS by applying innovative therapeutics in order to prevent organ dysfunction or limit progression into organ failure. The firm's complement system is activated and produces large amounts of products including complement 5a (C5a), C3a, C4a and membrane-attack complex (MAC). The company was founded in 2007 by Niels Riedemann and Renfeng Guo and is headquartered in Jena, Germany. |
Biotechnology
|
Sektor
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+20,17 % | 127 Mrd. | |
+24,67 % | 117 Mrd. | |
+25,44 % | 27,67 Mrd. | |
-17,74 % | 20,33 Mrd. | |
-15,17 % | 16,79 Mrd. | |
-15,21 % | 15,63 Mrd. | |
+11,91 % | 14,84 Mrd. | |
-47,10 % | 14,65 Mrd. | |
+54,50 % | 14,43 Mrd. |
- Börse
- Aktien
- A2H7A5 Aktie
- A2H7A5 Aktie
- Unternehmen InflaRx N.V.